IF-MCT16:8: IF-MCT 16:8: Investigating the Influence of Intermittent Fasting With and Without MCTs in Patients With Drug-resistant Epilepsy

Sponsor

University Hospital Marburg (Other)

Overall Status

Recruiting

CT.gov ID

NCT06013761

Collaborator

(none)

Enrollment

Location

Arms

29.2

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The objective of the prospective monocentric pilot trial is to investigate the influence of intermittent fasting with or without a once-daily intake with medium chain triglycerides (MCTs) on the frequency of seizures in patients with therapy-refractory epilepsy. The effects of 12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared to 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover-design in 28 patients with drug-resistant epilepsy.

Condition or Disease	Intervention/Treatment	Phase
Epilepsy Intermittent Fasting	Other: IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm	N/A

Detailed Description

One in three patients suffering epilepsy does not become seizure-free with conventional pharmacotherapy. The chance of seizure freedom with each additional medication is only in the single-digit percentage range. For this reason, additive therapies such as the ketogenic diet play an important role. By means of a ketogenic diet, a significant reduction in the frequency of seizures has been shown in various studies for children. The main goal is the body's own production of ketone bodies in the liver, which are used instead of glucose to produce the energy carrier ATP. This metabolic change results in biochemical, metabolic and hormonal changes that may reduce the severity and frequency of epileptic seizures, although the exact mechanisms are not yet understood. Common to all forms of ketogenic diets (e.g. classic kKD, modified Atkins diet, low glycemic index diet) is a specific preparation of each meal with plans for meals and often an initiation of additive therapy in the inpatient setting or by trained staff. Especially in adulthood, the lack of treatment adherence seems to play an important role in the effectiveness of the ketogenic diet. A form of ketogenic diet which might be more suitable for everyday use is intermittent fasting.

The primary aim of the prospective monocentric pilot trial is to investigate the effect of intermittent fasting with and without a once-daily intake of medium-chain triglycerides (MCTs) on the frequency of seizures in patients with therapy-refractory epilepsy. The effects of 12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared to 12 weeks intermittent fasting with additional intake of exogenous medium chain triglycerides (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. Secondarily, the influence of this diet on the composition of the gut microbiome, the T-cell mediated innate immune system and neuronal signalling pathways and networks will be investigated.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

28 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Monocentric Randomized Experimental Pilot Trial Investigating the Influence of Intermittent Fasting According to the 16:8 Method With and Without Medium-chain Triglycerides (MCTs) on Seizure Frequency, Biomarkers and Neural Networks in Patients With Drug-resistant Epilepsy

Actual Study Start Date :

Jul 25, 2023

Anticipated Primary Completion Date :

Dec 31, 2025

Anticipated Study Completion Date :

Dec 31, 2025

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: IF 16:8 12 weeks intermittent fasting according to the 16:8 method (IF 16:8)	Other: IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm 12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.
Experimental: IF MCT 16:8 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8)	Other: IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm 12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.

Arm

Intervention/Treatment

Active Comparator: IF 16:8

12 weeks intermittent fasting according to the 16:8 method (IF 16:8)

Other: IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm

12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.

Experimental: IF MCT 16:8

12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8)

Other: IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm

Outcome Measures

Primary Outcome Measures

Effect of intermittent fasting according to the 16:8 method with and without exogenous MCTs on seizure frequency in drug-resistant epilepsy [3 months]
Monthly seizure frequency is recorded using standardized seizure diaries.

Secondary Outcome Measures

Effect of intermittent fasting according to the 16:8 method on therapy adherence in patients with drug-resistant epilepsy [3 months]
The nutritional behavior during the studio is recorded using a standardized daily nutrition diary.
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on ketosis in patients with drug-resistant epilepsy [3 months]
All participants measure their ketosis weekly with a standardized ketosis device during the fasting episode and document this in a ketosis table provided.
Effect of intermittent fasting according to the 16:8 method on self-efficacy in patients with drug-resistant epilepsy [3 months]
Self-efficacy is determined using the scale of general self-efficacy expectation (Jerusalem & Schwarzer). This includes 10 items with 4 degrees. High scores mean a high level of general self-efficacy expectation.
Effect of intermittent fasting according to the 16:8 method on life-quality in patients with drug-resistant epilepsy [3 months]
Life-quality is measured using the standardized questionnaire on life quality.
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on biomarkers in patients with drug-resistant epilepsy [3 months]
The metabolome is examined using a mass spectroscopic blood sample. The microbiome is examined using a standardized stool sample using next-generation sequencing.
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on neural networks in patients with drug-resistant epilepsy [3 months]
Neural networks are measured using magnetic resonance imaging (diffusion tensor imaging and resting state MRI).
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on immune status in patients with drug-resistant epilepsy [3 months]
The immune status and in particular the T-cell mediated innate immune response is determined serologically.
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on fatigue in patients with drug-resistant epilepsy [3 months]
Fatigue is measured using the standardized Fatigue-Impact-Scale (FIS)-Test.
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on attention in patients with drug-resistant epilepsy [3 months]
Attention is measured using the standardized test battery for attention testing (TAP-Test).
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on neurotransmitter gamma-aminobutyric acid (GABA)in patients with drug-resistant epilepsy [3 months]
The change in the neurotransmitter GABA is examined serologically over the period of the study phase.
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on stress response in patients with drug-resistant epilepsy [3 months]
Stress response in hair cortisol of all participants is recorded using several hair samples.
Effect of intermittent fasting according to the 16:8 method with exogenous MCTs on intima media thickness in patients with drug-resistant epilepsy [3 months]
Intima media thickness of all participants will be recorded with a duplex sonographic examination of the arteries supplying the brain.